Can MRI predict breast cancer treatment success?

NCT ID NCT03738553

Terminated Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether special MRI scans can detect early signs that anti-HER2 therapy is working in women with HER2-positive breast cancer. Thirteen participants received one dose of trastuzumab before surgery, and researchers compared MRI changes to immune cell levels in the tumor. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab
What this could lead to: If successful, this could help doctors use MRI to quickly tell if anti-HER2 therapy is working, potentially guiding treatment decisions.
What could go wrong: This was a very small, terminated study with only 13 participants. The results may not apply to larger groups, and the approach may not prove reliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.